StockData

Oscar Health vs Trupanion

OSCR and TRUP side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OSCR and TRUP compare

Oscar Health is the larger company, worth 6.1 times as much as Trupanion ($9.7B against $1.6B).

On earnings, Oscar Health is cheaper: it trades at 22.4× trailing earnings, against 68.2× for Trupanion.

Oscar Health grew revenue faster over the last twelve months (42.8% versus 11.8% for Trupanion).

Oscar Health scores higher on the StockData Score (11 against 6 for Trupanion), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOSCRTRUP
Size and price
Market cap$9.7B$1.6B
Share price$31.33$36.16
Change, 1 year125%−8.2%
Change, 5 years219%−71.5%
Beta (5Y)2.100.05
Employees2,3051,121
StockData Score
Total score11 (better)6
Valuation score1 (better)0
Growth score23 (better)
Performance score4 (better)0
Health score4 (better)3
Dividend score00
Valuation
P/E22.4× (better)68.2×
P/S0.6× (better)1.0×
P/B4.7×3.9× (better)
EV/EBITDA2.4× (better)32.7×
P/FCF2.2× (better)19.3×
FCF yield45.3% (better)5.2%
Fair value$24.56$22.25
Margin of safety−27.6% (better)−62.5%
Growth
Revenue growth (TTM)42.8% (better)11.8%
Revenue growth, 5Y average90.8% (better)23.4%
EPS growth (TTM)–104%
Profitability
Gross margin–16.6%
Operating margin4.1% (better)1.6%
Net margin3.6%–
FCF margin28.6% (better)5.4%
Return on equity34.3%–
Return on invested capital–18.9%
Financial health
Debt / equity0.21 (better)0.26
Net debt / EBITDA−12.35−7.36
Interest coverage39.7× (better)2.3×
Current ratio1.081.77 (better)
Altman Z-score1.973.66 (better)
Piotroski F-score4–
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions64.7%77.1%
Held by insiders20.9%5.7%
Insider net buying, 12 months−$132M−$3.1M (better)
Short interest, % of float6.9%9.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.